FGI-106-tetrahydrochloride

Category	Hepatitis C Virus (HCV)
CAS	1149348-10-6
Description	FGI-106 tetrahydrochloride is a potent and broad-spectrum inhibitor with inhibitory activity against multiple viruses. FGI- 106 tetrahydrochloride is active against Ebola, Rift Valley and Dengue Fever viruses with EC50s of 100 nM, 800 nM and 400-900 nM, respectively. FGI-106 tetrahydrochloride also inhibits non-hemorrhagic fever viruses HCV and HIV-1 with EC50s of 200 nM and 150 nM, respectively.

Quotation Now

Synonyms	FGI-106 (tetrahydrochloride)\|CS-0127862
Molecular Weight	604.49
Molecular Formula	C28H42Cl4N6
Purity	99.46%
Solubility	In Vitro: DMSO : 6.67 mg/mL(11.03 mM;ultrasonic and warming and adjust pH to 2 with HCl and heat to 60°C) In Vivo: 1.Add each solvent one by one:10% DMSO >> 40%PEG300 >> 5%Tween-80 >> 45% saline Solubility: ≥ 0.67 mg/mL (1.11 mM); Clear solution 2.Add each solvent one by one:10% DMSO >> 90% (20%SBE-β-CDin saline) Solubility: ≥ 0.67 mg/mL (1.11 mM); Clear solution
Appearance	Light brown to brown (Solid)
Storage	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months -20°C, 1 month (sealed storage, away from moisture)
In Vitro	Treatment with 2 μM FGI-106 mediated a 4 log reduction in infectious viral titers relative to matched controls, with an EC90 for inhibition of viral killing of host cells (Vero E6 cells) estimated to be 0.6 μM. In cell-based assays, treatment with FGI-106 inhibits viral replication by divergent virus families, including positive and negative-strand RNA viruses.
In Vivo	FGI-106 (0.1-5 mg/kg; intraperitoneal injection; treatments on days 2 and 5; C57BL/6 or BALB/c mice) treatment decreases mortality from Zaire EBOV in a dose-dependent manner. Result: Decreased mortality from Zaire EBOV in a dose-dependent manner.
Target	EC50: 100 nM (Ebola virus), 800 nM (Rift Valley virus), 400-900 nM (Dengue Fever virus), 200 nM (HCV) and 150 nM (HIV-1)